Market watchers identify four notable equities—MRNA, GILD, JBLU, and LLY—as key positions to track over the upcoming trading week amid shifting sector dynamics.

The U.S. Food and Drug Administration has approved Gilead Sciences’ new once-daily combination medication for treating HIV infection. The approval aims to simplify long-term antiretroviral therapy and improve patient adherence.

Gilead's core business is showing acceleration, but analysts are questioning whether its significant $11 billion pipeline investment will yield expected returns.

An analysis compares the growth trajectories of pharmaceutical giants Pfizer and Gilead, evaluating which company presents a stronger long-term growth story. The comparison focuses on their respective market positions and future potential.

Gilead Sciences has seen its stock price increase for the seventh straight trading session.

The article examines if MacroGenics (MGNX) can transform Gilead Sciences (GILD)'s $10 million milestone payment into a significant catalyst for its pipeline development.

Seeking Alpha analysts have issued a series of upgrades and downgrades for several prominent technology companies, including Intel (INTC), AMD, Arista Networks (ANET), and Gilead Sciences (GILD).

Several companies, including Elanco, Super Group, Amprius Technologies, Amgen, and Gilead, have either raised or updated their financial outlooks for fiscal year 2026, with many reporting beats on top-line and bottom-line estimates. These updates include revised revenue projections, EPS guidance, and growth targets.

Gilead Sciences presented its second-quarter earnings call highlights, discussing its financial performance and updates on its pharmaceutical pipeline.

A new drug called lenacapavir, developed by Gilead Sciences, has shown nearly 100% effectiveness in preventing HIV infection with a twice-a-year injection, now facing the challenge of patient access.

Gilead is collaborating with cultural influencers to raise awareness about HIV stigma and promote HIV prevention, emphasizing advocacy alongside scientific advancements.

Many investors are still treating Gilead Sciences as a legacy HIV stock, but the company's four new drug launches this year could significantly change its market perception and valuation.

Financial analysis is being conducted on various NASDAQ stocks, with discussions on whether Nvidia is undervalued or AMD is overvalued. Several companies, including Viatris, Biogen, and Gilead, are being identified as potentially undervalued stocks to buy right now.

A potential FDA milestone could unlock a significant new growth driver for Gilead Sciences (GILD).

The U.S. Food and Drug Administration (FDA) has accepted Gilead's supplemental New Drug Application (sNDA) for its weekly Yeztugo HIV pill.

Pharmaceutical companies Merck and Gilead have reported positive outcomes from their Phase 3 clinical trials for a new combination pill designed to treat HIV.

Gilead Sciences and Lakefront have successfully finalized the acquisition of Ouro Medicines, a move expected to impact their respective portfolios and market positions.

An analysis examines the stock performance of Gilead Sciences in comparison to other companies within the healthcare sector. The report evaluates how Gilead's shares are faring relative to its industry counterparts.

Gilead Sciences has secured FDA approval for Hepcludex, marking it as the first approved treatment for hepatitis delta virus (HDV), offering a new therapeutic option for patients.

Maxim has upgraded Gilead Sciences (GILD) to a ‘Buy’ rating. This reflects a positive outlook on the pharmaceutical company's stock.

Gilead Sciences has announced the pricing of its multi-tranche senior notes offering, totaling $3 billion.

Gilead Sciences' stock declined despite beating Q1 estimates, as the company now anticipates a loss per share for 2026.

Gilead Sciences held its annual meeting, where directors and executive pay received significant approval. The company also highlighted upcoming pipeline launches and potential acquisitions.

The TV series 'The Testaments,' based on Margaret Atwood's sequel to 'The Handmaid's Tale,' follows the fates of a new generation of enslaved women in Gilead.

Jim Cramer offered his latest investment advice, highlighting specific stock recommendations like Wells Fargo, Nokia, and Broadcom, and shared his outlook on the market's "remarkable" rally and the upcoming big earnings week. He also discussed strategic moves for his Investing Club.

Morgan Stanley has adjusted its outlook for Gilead Sciences, Inc. in anticipation of the company's first-quarter earnings report.

Gilead (GILD) and Tempus AI (TEM) have announced an expansion of their multi-year collaboration in oncology research and development.

Morgan Stanley has increased its price target for Vertex Pharmaceuticals to $612 from $596, indicating a positive outlook for the company's stock.

Seeking Alpha analysts have released their latest stock recommendations, including upgrades and downgrades for companies such as Palantir (PLTR), Rivian (RIVN), Gilead Sciences (GILD), and Intel (INTC). Additionally, unusual put options volume for Intel (INTC) has been observed, interpreted by some as a bullish signal for the company.

The sequel to 'The Handmaid's Tale,' titled 'The Testaments,' has been released, focusing on young women being prepared for marriage at an elite preparatory school in Gilead, led by Aunt Lydia.

Lucy Halliday, a breakout actress from 'The Testaments,' discusses her experience learning from James McAvoy and sharing screen time with Chase Infiniti.

An analysis explores whether Gilead Sciences (GILD) qualifies as a top low-volatility blue-chip stock for current investment portfolios.

The spin-off series 'The Testaments,' based on 'The Handmaid's Tale,' is scheduled for release, continuing the narrative set in the totalitarian society of Gilead where women are deprived of their rights.

Galapagos NV announced it has signed an agreement with Gilead Sciences concerning assets related to Ouro Medicines. The details of the agreement were not immediately specified.

Galapagos NV and Gilead Sciences have entered into an agreement concerning the acquisition of Ouro Medicines, signaling a new development in the pharmaceutical sector.

US biopharmaceutical company Gilead Sciences has agreed to acquire Ouro Medicines for up to US$2.18 billion, gaining rights to an antibody-based medicine for autoimmune diseases licensed from China’s Keymed Biosciences.

This week, Elisabeth Moss and Lindsey McManus are celebrating the debut of Apple TV’s “Imperfect Women,” the first project the pair picked up after launching their Love & Squalor production banner…

Gilead Sciences, Inc. (GILD) is seeing its growth prospects bolstered by recent analyst upgrades, indicating positive sentiment in the market.

Os projetos selecionados abrangem as áreas do VIH, hepatites virais crónicas, cancro da mama e linfoma não hodgkin de células B. Ao todo, foram recebidas 47 candidaturas de diversas entidades.

Hulu reveals the first trailer for The Testaments.

The highly anticipated follow-up from Hulu, premiering April 8, stars Chase Infiniti as the daughter to Elisabeth Moss' heroine who is growing up in Gilead.

The company studied the pill in HIV patients whose virus was already suppressed, including those switching from complex multi-tablet regimens or from a guideline-recommended single-tablet treatment

Gilead Sciences has announced the acquisition of Arcellx, a company specializing in CAR-T cell therapies, in a deal valued at $7.8 billion.

Gilead Sciences announced its plan to acquire cancer drug developer Arcellx in a deal valued at up to $7.8 billion, as pharmaceutical groups continue to acquire smaller biotech firms.

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion  Reuters

Analysts are sharing their opinions and insights on Gilead Sciences (GILD) following its recent earnings report.

The U.S. Food and Drug Administration has granted approval for Gilead Sciences' new once-daily oral medication for treating HIV.

Pharmaceutical giant Gilead Sciences is experiencing a significant financial recovery after overcoming a prolonged period of declining performance. Analysts attribute the turnaround primarily to a key product or strategic initiative that is driving substantial revenue growth.

Gilead Sciences is experiencing a surge in its HIV business, prompting questions about whether the company is becoming overly dependent on a single franchise for its overall success.

Gilead Sciences has quietly become recognized as one of the most underrated turnaround stories in the healthcare sector, generating excitement on Wall Street.

A U.S. appeals court has sided with Gilead Sciences, ruling against companies known as alternative funding programs that import medicines from overseas. This decision impacts the ability of these programs to bring Gilead medications into the country.

Bank of America has expressed support for Gilead Sciences, citing a key HIV statistic that is reportedly over 70%.

Gilead Sciences has announced a dividend of $0.82 per share.

Gilead Sciences reported an 8% increase in second-quarter sales, successfully beating Wall Street's financial estimates.

A head-to-head clinical trial has demonstrated that ViiV Healthcare's Dovato is as effective as Gilead Sciences' Biktarvy, indicating comparable efficacy between the two treatments.

Morgan Stanley has reiterated its 'Buy' rating for Gilead (GILD), indicating a continued positive outlook on the company's performance.

Cantor Fitzgerald has reiterated its Overweight rating on Gilead Sciences (GILD) following positive results from its HIV trial.

An Israeli study titled 'From Myth to Model: Representation of “The Jew” in Generative AI' by academics Michael Gilead and Gal Gutman revealed that modern AI systems embed centuries-old antisemitic tropes.

Costume designers for shows like 'The Testaments' and 'Fallout' discuss how they use color, tailoring, and texture to build the distinct worlds of TV's most stylish dystopias.

An article provides an analysis on whether Gilead Sciences, Inc. (GILD) stock is currently a good investment for potential buyers.

Gilead Sciences has released new findings from a post hoc analysis, providing additional data related to their research.

Gilead Sciences (GILD) is scheduled to showcase new data related to its cancer therapy research, indicating potential advancements in oncology.

An article explores how the women of Gilead are defined by their clothes in 'The Testaments,' the sequel to 'The Handmaid's Tale,' highlighting the symbolic significance of their attire.

A novelist, inspired by a visit to an island brothel in Bangladesh, explores radical fictional worlds where women hold power, highlighting how rebellious female characters in literature can provide hope.

Morgan Stanley has reevaluated its outlook for Gilead Sciences following the company's recent quarterly report, providing an updated perspective on its financial performance and future prospects.

Gilead Sciences, Inc. (GILD) has seen its outlook cut sharply due to significant $11.5 billion IPR&D (In-Process Research and Development) and financing costs, impacting its financial projections.

Gilead Sciences has revised its 2026 sales forecast upwards but simultaneously lowered its profit outlook, citing recent acquisitions as the primary reason for the adjustments.

Analysts are divided on the future performance of Gilead Sciences stock, with varying bullish and bearish sentiments from Wall Street.

Gilead Sciences is reportedly set to acquire Arcellx, a move that would expand Gilead's portfolio and strategic capabilities within the biopharmaceutical sector.

Citi has increased its price target for Gilead Sciences (GILD) in anticipation of the company's upcoming Q1 Biopharma preview.

Gilead Sciences has once again extended its tender offer to acquire Arcellx.

This article provides a summary of notable healthcare headlines for the week, focusing on companies such as Organon, Eli Lilly, and Gilead.

Gilead Sciences is projecting a $107 million headwind to its first-quarter earnings, attributed to recent research and development deals.

Analysts have released their latest stock recommendations, including upgrades and downgrades for companies such as Palantir, Rivian, Gilead Sciences, and Intel, alongside a specific buy prediction for QuantumScape (QS) stock before April 22, and analysis on Tesla's recent pullback.

Bruce Miller, creator of 'The Testaments,' is delving back into the world of Gilead, discussing the continuation of 'The Handmaid's Tale' story, the return of Elisabeth Moss as June, and the casting of Chase Infiniti and Stephen Colbert.

The sequel to Margaret Atwood's 'The Handmaid's Tale,' titled 'The Testaments,' is being described as a 'magnificent coming-of-age' story. Chase Infiniti is noted for bringing an 'electric A-lister aura' to the narrative.

Gilead Sciences has provided details on its deals with Tubulis, Ouro, and Arcellx, which are seen as pipeline catalysts, with further updates expected by 2026.

Gilead Sciences announced its intention to acquire Tubulis, a company specializing in antibody-drug conjugates (ADCs), in a deal valued at $5 billion, expanding its oncology pipeline.

Investors are anticipating several key earnings reports from major companies, including PG&E Corporation, Procter & Gamble, CenterPoint Energy, and Gilead Sciences, that are set to be released after the market closes on Thursday.

Gilead Sciences has announced its intention to acquire Ouro Medicines in a deal valued at $2.18 billion, aiming to expand its pipeline of treatments for inflammatory diseases.

Gilead Sciences has announced plans to acquire Ouro Medicines and will subsequently collaborate with Galapagos on the assets obtained through the purchase.

“The Handmaid’s Tale” sequel “The Testaments,” based on a 2019 novel by Margaret Atwood, is expanding the Gilead universe.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD)  The Globe and Mail

Wall Street analysts have issued new ratings for biopharma companies, with Gilead receiving a 'Buy' recommendation, Amgen a 'Hold', and ORIC gaining a vote of confidence.

Hulu has released the trailer for “The Testaments,” the upcoming sequel series to “The Handmaid’s Tale.” “The Testaments” is set to premiere on April 8 with three episodes and is based on author…

South Africa seeks local production of Gilead's HIV prevention drug  Reuters

An international clinical trial, involving five Spanish hospitals, is testing a new single-pill daily treatment for HIV.

Gilead Sciences has announced a $7.8 billion payment to take full control of a promising multiple myeloma therapy, expanding its oncology portfolio.

Gilead Sciences has announced its acquisition of Arcellx in a deal valued at up to $7.8 billion.

Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its presence in the biotechnology sector.

Gilead Sciences board member Welters sold roughly $2.68 million in company shares.

The European Union has approved Gilead's Trodelvy in combination with Keytruda for the first-line treatment of breast cancer. This approval marks a significant development in cancer therapy.

Gilead Sciences is experiencing accelerating revenue growth, but questions are being raised regarding the cost-effectiveness and value of its recent acquisitions. The company's financial strategy is under evaluation.

Multinational pharmaceutical company Gilead Sciences will cease the circulation of an innovative breast cancer drug in Greece starting January 1, 2027, citing a clawback mechanism that exceeds 100%.

Gilead has achieved a significant victory in a major court ruling, effectively removing a challenge or obstacle for the company.

A potential partnership between Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD) is being explored as a possible new engine for growth in the pharmaceutical industry.

Gilead Sciences reported a 10% jump in Q2 base sales, driven by strong growth in its HIV and oncology segments, despite a decline in Veklury sales.

Gilead Sciences is evaluating Yeztugo as a potential significant growth driver for its HIV treatment portfolio, indicating a focus on expanding its market presence in the sector.

Pharmaceutical companies Johnson & Johnson and Gilead Sciences were among those receiving drug recommendations from the European Union this week. These recommendations are part of the EU's regulatory process for new and existing medicines.

An article explores whether the current bearish sentiment surrounding pharmaceutical giants Pfizer and Gilead Sciences presents a potential contrarian investment opportunity.

Yahoo reports on Monday's top Wall Street analyst research calls, covering various companies including Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, and T-Mobile.

Gilead's drug Trodelvy has received approval for new indications in the treatment of breast cancer, expanding its potential use for patients.

Gilead Sciences (GILD) has made a donation of Remdesivir to Uganda, contributing to public health efforts in the country.

Chase Infiniti discusses keeping her role in 'The Testaments' a secret from co-stars and her experience playing Elisabeth Moss's daughter in the series, set in Gilead's teen-girl wasteland.

Gilead Sciences (GILD) and Lakefront Biotherapeutics have jointly acquired Ouro Medicines to further advance their pipeline of autoimmune treatments.

Gilead Sciences' drug Livdelzi has garnered attention for demonstrating long-term efficacy and safety in its trials.

Gilead Sciences has acquired Tubulis for $3.15 billion, a strategic move aimed at expanding its oncology portfolio. This acquisition underscores Gilead's commitment to strengthening its presence in cancer treatment and research.

Gilead Sciences' drug Hepcludex has received FDA approval for the treatment of chronic Hepatitis Delta Virus (HDV) infection, marking a significant development in health.

Gilead Sciences anticipates reporting a loss this year, primarily driven by significant expenses related to acquired research and development.

Gilead Sciences is targeting $1 billion in sales for its drug Yeztugo by 2026 and has raised its overall base business outlook to between $29.4 billion and $29.8 billion.

Ann Dowd and Mabel Li, stars of 'The Testaments,' delve into the dark pasts of their characters, Aunt Lydia and Aunt Vidala, and the origin story of Gilead's 'Aunts' program in a new interview.

Gilead Sciences Inc. is reportedly increasing in popularity as a defensive stock choice among investors, indicating its perceived stability in the market.

Morgan Stanley has revised its outlook for Gilead Sciences, citing updated biopharma models that suggest a more positive financial trajectory for the company.

Several significant business deals were announced this week, involving companies such as Organon, UMG, Whitestone REIT, and Gilead, among others.

Gilead Sciences (GILD) announced its intention to acquire Tubulis for $5 billion, a strategic move to strengthen its oncology drug pipeline.

Truist has adjusted its price target for BeOne Medicines, lowering it to $411 from $412. This change indicates a revised valuation perspective for the pharmaceutical company.

The creators and stars of the Hulu and MGM adaptation of Margaret Atwood's "The Testaments" discuss book changes and a surprise connection to "The Handmaid's Tale," launching the next chapter of Gilead's story.

A review of Margaret Atwood's 'The Testaments' describes the novel as a dark and bloody sequel to 'The Handmaid’s Tale', continuing the story of June's daughter in Gilead.

Hulu's upcoming 'Handmaid's Tale' spinoff, 'The Testaments,' will explore the theme of girlhood within the dystopian society of Gilead.

Gilead has reached an agreement to purchase the cancer biotechnology company Tubulis in a deal valued at $5 billion.

Galapagos has announced a partnership with Gilead on the drug Gamgertamig, a deal that unlocks $500 million in cash and sets sights on registrational trials by 2027.

Gilead Sciences has announced its acquisition of Ouro Medicines and a subsequent collaboration with Galapagos on the newly purchased assets, as reported by the Wall Street Journal.

The ladies of Gilead were in France, Saturday, for the world premiere of Hulu’s The Testaments.

A biotech company's $64 million exit reportedly missed a significant 77% one-day surge following a takeover deal by Gilead, indicating a potential miscalculation in the timing of the transaction.

After years of waiting, the saga of the totalitarian regime of Gilead gets its continuation.

In a dramatic departure from its predecessor, Hulu and MGM's coming-of-age next Margaret Atwood adaptation feels significantly lighter, even bordering on whimsical — before the cracks of resistance…

When you’re young and thinking of your life, it’s normal to envision fluffy white clouds, sunshine and rainbows. However, if you grew up in Gilead, your reality is much darker.

A report highlights notable healthcare headlines for the week, focusing on developments related to pharmaceutical companies Viatris, Novo Nordisk, and Gilead Sciences.

Gilead Sciences' experimental HIV treatment has demonstrated low discontinuation rates in recent studies, indicating potential for improved patient adherence.

Gilead Sciences has announced its intention to acquire Arcellx, a developer of cancer therapies, in a deal valued at up to $7.8 billion.

Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its portfolio in the biotechnology sector.

Barclays has adopted a neutral stance on Gilead Sciences, acknowledging its strategic refocus but maintaining a cautious outlook.